Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Sarepta Therapeutics (GB:0L35)
LSE:0L35
RESEARCH TOOLSreports
Sarepta Therapeutics (0L35) Share Price & Analysis
1 Followers
0L35 Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$55.68 - $155.48
Previous Close$117.97
Volume150.00
Average Volume (3M)260.00
Market Cap
$11.06B
Enterprise Value$10.79B
Total Cash (Recent Filing)$1.68B
Total Debt (Recent Filing)$1.40B
Price to Earnings (P/E)-19.2
Beta0.78
Next Earnings
May 01, 2024EPS Estimate
-$0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.16
Shares Outstanding93,855,410
10 Day Avg. Volume463
30 Day Avg. Volume260
Standard Deviation0.20
R-Squared0.07
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)12.81
Price to Sales (P/S)21.10
Price to Cash Flow (P/CF)-50.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue8.67
Enterprise Value/Gross Profit7.74
Enterprise Value/Ebitda-23.13
Forecast
1Y Price Target
$169.47Price Target Upside43.66% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
Sarepta Therapeutics News
PremiumPre-Earnings
Is SRPT a Buy, Before Earnings?
Bulls Say, Bears Say
Bulls Say
Market PotentialRapid development in LGMD with accelerated approval could lead to faster market access.
Partnership SynergiesPartner Roche plans to submit a BLA in mid-2024, with EMA submissions on track for the same period, potentially expanding the patient base.
Regulatory MilestoneAnalyst maintains a Buy-rating, believing Elevidys has a high likelihood for broad label expansion and strong adoption.
Bears Say
CompetitionREGENXBIO's updated data disclosed higher microdystrophin expression and more robust reductions in CK levels, indicating potential competition.
GuidanceSarepta guided to flattish Q/Q Elevidys sales due to limited eligible newly diagnosed 4-5 y/o DMD patients.
Safety ConcernsSafety data were more questionable, with serious treatment-emergent adverse events pointing to potential kidney toxicity and electrolyte deficiencies.
---
Options Prices
Currently, No data available
---
Ownership Overview
47.65% Insiders
36.88% Mutual Funds
13.43% Other Institutional Investors
2.05% Public Companies and
Individual Investors
0L35 FAQ
What was Sarepta Therapeutics’s price range in the past 12 months?
Sarepta Therapeutics lowest share price was $55.68 and its highest was $155.48 in the past 12 months.
What is Sarepta Therapeutics’s market cap?
Currently, no data Available
When is Sarepta Therapeutics’s upcoming earnings report date?
Sarepta Therapeutics’s upcoming earnings report date is May 01, 2024 which is in 12 days.
How were Sarepta Therapeutics’s earnings last quarter?
Sarepta Therapeutics released its earnings results on Feb 28, 2024. The company reported $0.47 earnings per share for the quarter, beating the consensus estimate of $0.069 by $0.401.
Is Sarepta Therapeutics overvalued?
According to Wall Street analysts Sarepta Therapeutics’s price is currently Undervalued.
Does Sarepta Therapeutics pay dividends?
Sarepta Therapeutics does not currently pay dividends.
What is Sarepta Therapeutics’s EPS estimate?
Sarepta Therapeutics’s EPS estimate is -$0.02.
How many shares outstanding does Sarepta Therapeutics have?
Sarepta Therapeutics has 93,855,410 shares outstanding.
What happened to Sarepta Therapeutics’s price movement after its last earnings report?
Sarepta Therapeutics reported an EPS of $0.47 in its last earnings report, beating expectations of $0.069. Following the earnings report the stock price went down -4.457%.
Which hedge fund is a major shareholder of Sarepta Therapeutics?
Among the largest hedge funds holding Sarepta Therapeutics’s share is Farallon Capital Management, L.L.C.. It holds Sarepta Therapeutics’s shares valued at 117M.
---
Sarepta Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$169.47 (43.66% Upside)
$169.47 (43.66% Upside)
Blogger Sentiment
Bullish
GB:0L35 Sentiment 84%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $3.1M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-5.84%
12-Months-Change
Fundamentals
Return on Equity
-86.15%
Trailing 12-Months
Asset Growth
4.35%
Trailing 12-Months
Company Description
Sarepta Therapeutics
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.
---
0L35 Earnings Call
Q4 2024
0:00 / 0:00
---
0L35 Stock 12 Months Forecast
Average Price Target
$169.47
▲(43.66% Upside)
Technical Analysis
Sarepta Therapeutics
―
Alnylam Pharma
―
Bluebird Bio
―
uniQure
―
Crispr Therapeutics AG
―
Best Analysts Covering 0L35
1 Year
1 Year Success Rate
33/47 ratings generated profit
1 Year Average Return
+19.21%
reiterated a buy rating 2 months ago
Copying Brian Skorney's trades and holding each position for 1 Year would result in 70.21% of your transactions generating a profit, with an average return of +19.21% per trade.
---